Sarepta Therapeutics announced the FDA has accepted supplemental New Drug Applications to convert accelerated approvals for Duchenne muscular dystrophy therapies AMONDYS 45 and VYONDYS 53 to traditional approvals. The PDUFA action date is set for 28 February 2027. The applications are supported by the ESSENCE confirmatory study and real-world evidence from over 1,800 treated patients. This could strengthen the regulatory foundation of Sarepta's exon-skipping franchise. The development may help diversify Sarepta's regulatory position in DMD treatment, potentially offsetting concentration risk around its ELEVIDYS therapy. ELEVIDYS recently received an FDA boxed warning for acute liver injury in November 2025. Sarepta's narrative projects $1.4 billion revenue and $87.3 million earnings by 2029, requiring a 13.3% yearly revenue decline from current levels.

Sarepta Therapeutics reported statutory profits that disappointed investors, with underlying concerns emerging from the earnings analysis. The company increased its share count by 7.4% over the past year, diluting per-share returns despite generating net income. The biotechnology firm was unprofitable three years ago and last year, making year-on-year growth comparisons difficult. Whilst the company achieved profit over the last 12 months, earnings per share would have been stronger without the share dilution. Additionally, Sarepta's profit received a significant boost from unusual items worth $52 million in the last 12 months. These one-off contributions may make statutory profit a poor indicator of underlying earnings power. The combination of share dilution and unusual items raises questions about the sustainability of the company's reported profitability.

Sarepta Therapeutics reported Q1 2026 revenue of $730.8 million, down 1.9% year-over-year, but exceeding the consensus estimate of $467.85 million by 56.2%. The biotechnology company posted earnings per share of $3.16, compared to a loss of $3.42 in the prior-year quarter, surpassing the consensus estimate of $0.90 by 253%. Product revenue totalled $330.52 million, slightly above analyst estimates of $325.88 million, representing a 46% year-over-year decline. PMO Products generated $228.55 million, whilst ELEVIDYS contributed $101.97 million, exceeding expectations despite a 72.8% year-over-year decrease. Shares have fallen 5.6% over the past month. The stock currently holds a Zacks Rank of Hold.